Download
file.pdf 3,40MB
WeightNameValue
1000 Titel
  • Comparative proteomic study reveals the enhanced immune response with the blockade of interleukin 10 with anti-IL-10 and anti-IL-10 receptor antibodies in human U937 cells
1000 Autor/in
  1. Ni, Guoying |
  2. Chen, Shu |
  3. Yuan, Jianwei |
  4. Walton, Shelley |
  5. Wei, Ming Q. |
  6. Li, Hejie |
  7. Pan, Xuan |
  8. Liu, Xiaosong |
  9. Wang, Tianfang |
1000 Erscheinungsjahr 2019
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2019-03-21
1000 Erschienen in
1000 Quellenangabe
  • 14(3):e0213813
1000 Copyrightjahr
  • 2019
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1371/journal.pone.0213813 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428271/ |
1000 Ergänzendes Material
  • https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0213813#sec018 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Blocking cytokine interleukin 10 (IL-10) at the time of immunisation enhances vaccine induced T cell responses and improves control of tumour cell growth in vivo. However, the effect of an IL-10 blockade on the biological function of macrophages has not been explored. In the current paper, a macrophage precursor cell line, U937 cells, was selected to investigate the differential expression of proteins and relevant cell signalling pathway changes, when stimulated with lipopolysaccharide (LPS) in the presence of antibodies to IL-10 or IL-10 receptor. We used a quantitative proteomic strategy to investigate variations in protein profiles of U937 cells following the treatments with LPS, LPS plus human anti-IL10 antibody and anti-IL10R antibody in 24hrs, respectively. The LPS treatment significantly activated actin-related cell matrix formation and immune response pathways. The addition of anti-IL10 and anti-IL10R antibody further promoted the immune response and potentially effect macrophage survival through PI3K/AKT signalling; however, the latter appeared to also upregulated oncogene XRCC5 and Cajal body associated processes.
1000 Sacherschließung
lokal Macrophages
lokal Malignant tumors
lokal Immune response
lokal Gene ontologies
lokal Enzyme-linked immunoassays
lokal Antibody therapy
lokal Cancer treatment
lokal Antibodies
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/TmksIEd1b3lpbmc=|https://frl.publisso.de/adhoc/uri/Q2hlbiwgU2h1|https://frl.publisso.de/adhoc/uri/WXVhbiwgSmlhbndlaQ==|http://orcid.org/0000-0002-5857-6913|https://frl.publisso.de/adhoc/uri/V2VpLCBNaW5nIFEu|https://frl.publisso.de/adhoc/uri/TGksIEhlamll|https://frl.publisso.de/adhoc/uri/UGFuLCBYdWFu|https://frl.publisso.de/adhoc/uri/TGl1LCBYaWFvc29uZw==|http://orcid.org/0000-0002-4876-7767
1000 (Academic) Editor
1000 Label
1000 Förderer
  1. National Natural Science Foundation of China |
1000 Fördernummer
  1. 81472451;2016A020213001;2012AA100461;2015AG1003
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer National Natural Science Foundation of China |
    1000 Förderprogramm -
    1000 Fördernummer 81472451;2016A020213001;2012AA100461;2015AG1003
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6453302.rdf
1000 Erstellt am 2023-07-28T13:11:24.323+0200
1000 Erstellt von 337
1000 beschreibt frl:6453302
1000 Bearbeitet von 317
1000 Zuletzt bearbeitet 2023-08-07T10:40:06.149+0200
1000 Objekt bearb. Mon Aug 07 10:39:52 CEST 2023
1000 Vgl. frl:6453302
1000 Oai Id
  1. oai:frl.publisso.de:frl:6453302 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source